An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression
Abstract We sought to evaluate the efficacy and safety of budesonide (Budenofalk) in the treatment of patients with IgA Nephropathy. We conducted a prospective, interventional, open-label, single-arm, non-randomized study that enrolled 32 patients with IgAN at high risk of progression (BUDIGAN study...
Main Authors: | Bogdan Obrișcă, Alexandra Vornicu, Valentin Mocanu, George Dimofte, Andreea Andronesi, Raluca Bobeică, Roxana Jurubiță, Bogdan Sorohan, Nicu Caceaune, Gener Ismail |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-11-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-47393-1 |
Similar Items
-
Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis
by: Bogdan Obrișcă, et al.
Published: (2022-09-01) -
Inherited Risk Factors of Thromboembolic Events in Patients with Primary Nephrotic Syndrome
by: Gener Ismail, et al.
Published: (2020-05-01) -
Clinical Predictors of Preeclampsia in Pregnant Women with Chronic Kidney Disease
by: Bogdan Marian Sorohan, et al.
Published: (2020-04-01) -
Clinical Phenotypes and Predictors of Remission in Primary Membranous Nephropathy
by: Roxana Jurubiță, et al.
Published: (2021-06-01) -
Oral Furosemide and Hydrochlorothiazide/Amiloride versus Intravenous Furosemide for the Treatment of Resistant Nephrotic Syndrome
by: Georgiana Frățilă, et al.
Published: (2023-11-01)